| Designations: | Caki-2 | | Depositors: | J Fogh | | Biosafety Level: | 1 | | Shipped: | frozen | | Medium & Serum: | See Propagation | | Growth Properties: | adherent | | Organism: | Homo sapiens （human） | | Morphology: | epithelial
| | Source: | Organ: kidney
Disease: clear cell carcinoma | | Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. HTB-47 Caki-2 人腎透明細(xì)胞癌細(xì)胞 | | | | Restrictions: | The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.） The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.） Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone （212） 639-6181; （212） 717-3439. | | Tumorigenic: | Yes | | Antigen Expression: | Blood Type A; Rh- | | DNA Profile （STR）: | Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 10
D16S539: 9,13
D5S818: 11
D7S820: 12
THO1: 6
TPOX: 9,11
vWA: 16,17 | | Cytogenetic Analysis: | （P8） hypopentaploid to hypohexaploid （+A2, +A3, +B, +C, +D, +F, +G, -A） with abnormalities including dicentrics, acrocentric fragments, minutes, breaks, and large subocentric markers | | Isoenzymes: | AK-1, 1
ES-D, 1
G6PD, B
GLO-I, 1-2
Me-2, 1
PGM1, 1
PGM3, 1 | | Age: | 69 years | | Gender: | male | | Ethnicity: | Caucasian HTB-47 Caki-2 人腎透明細(xì)胞癌細(xì)胞 | | Comments: | This is another line isolated from a primary renal carcinoma by J. Fogh as indicated in the description for ATCC HTB-46.
According to the originator, Caki-2 was established from a primary clear cell carcinoma of the kidney. [21869]
Recent evaluation （K. Pulkkanen and J. Parkinen, personal communication） of nude mouse tumors formed by this line in orthotopic and s.c. implantations were consistent with cystic papillary renal cell carcinoma according to the criteria of Kovacs et al. [51548]
Ultrastructural features reported include microvilli and microfilaments with few mitochondria, lysosomes or lipid droplets.
Frequent multilamellar bodies were observed, but no virus particles were seen. | | Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. | | Subculturing: | Subc*tion Ratio: A subc*tion ratio of 1:3 to 1:6 is recommended
Medium Renewal: 2 to 3 times per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature （or at 37C） until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks. | | Preservation: | Culture medium, 95%; DMSO, 5% | | Related Products: | Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2007
recommended serum:ATCC 30-2020 | | References: | 21869: . Human tumor cells in vitro. New York: Plenum Press; 1975.
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
24381: Fogh J. C*tion, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl. Cancer Inst. Monogr. 49: 5-9, 1978. PubMed: 571047
51548: Kovacs G, et al. The Heidelberg classification of renal cell tumors. J. Pathol. 183: 131-133, 1997. PubMed: 9390023 |
|
14
